期刊
MITOCHONDRION
卷 13, 期 6, 页码 610-614出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.mito.2013.08.010
关键词
Mitochondria; Mitochondrial drug delivery; Mitochondrial targeting peptide; MITO-Porter; S2 peptide; Nanoparticles
资金
- Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation, Japan (NIBIO)
- Ministry of Education, Culture, Sports, Science and Technology of Japanese Government (MEXT)
- Grants-in-Aid for Scientific Research [23680053] Funding Source: KAKEN
To achieve mitochondrial therapy, we previously reported on the use of an octaarginine (R8) modified Dual Function (DF)-MITO-Porter for delivering molecules to mitochondria in living cells. In this study, using isolated mitochondria, homogenates and living cells, we evaluated the utility of mitochondrial targeting functional peptides as a ligand for delivering carriers. The S2 peptide modified carrier showed a high mitochondrial targeting activity in homogenates and living cells. In addition, the S2 peptide had a lower cell toxicity compared to R8 modified liposomes. The S2 peptide represents a potentially useful moiety for constructing an efficient and safe mitochondrial delivery system. (C) 2013 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据